TWO TOWER PLACE, SOUTH SAN FRANCISCO, CA
Amendment Approved to 2018 Stock Incentive Plan Increasing Shares to 2.68M
Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Reports First Quarter 2026 Financial Results and Recent Highlights
Annual Report to Security Holders
Assembly Biosciences Announces 2026 Corporate Bonus Plan Approval
Reports Year-End 2025 Financial Results and Recent Highlights
Assembly Biosciences Shows Positive Phase 1b Results for ABI-1179 and ABI-5366 in Genital Herpes
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload